Among the galectins analysed, LGALS1, LGALS3, and LGALS9 emerged as significantly upregulated in glioblastoma, consistent with prior studies identifying these molecules as key contributors to glioma progression and suggesting multifaceted roles in tumour progression and resistance mechanisms. This evidence concerns the gene LGALS1 and central nervous system cancer.